For the quarter ending 2025-09-30, CUE made $2,149,000 in revenue. -$7,447,000 in net income. Net profit margin of -346.53%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration revenue | 2,149,000 | 2,954,000 | 421,000 | 1,983,666.667 |
| General and administrative | 4,939,000 | 3,679,000 | 4,173,000 | 3,906,000 |
| Research and development | 4,754,000 | 7,910,000 | 8,547,000 | 8,971,333.333 |
| (gain) loss on fixed asset disposal | - | - | - | -1,333.333 |
| Loss (gain) on fixed asset disposal | -51,000 | - | - | - |
| Total operating expenses | 9,744,000 | 11,589,000 | 12,720,000 | 12,878,666.667 |
| Loss from operations | -7,595,000 | -8,635,000 | -12,299,000 | -10,895,000 |
| Interest income | 222,000 | 198,000 | 170,000 | 426,333.333 |
| Interest expense | -75,000 | -45,000 | -128,000 | -202,666.667 |
| Total other income, net | 147,000 | 153,000 | 42,000 | 223,666.667 |
| Net loss | -7,448,000 | -8,482,000 | -12,257,000 | -10,671,333.333 |
| Unrealized gain from available-for-sale securities | 1,000 | - | - | - |
| Comprehensive loss | -7,447,000 | -8,482,000 | -12,257,000 | -10,671,333.333 |
| Net loss per common share, basic | -0.07 | -0.09 | -0.17 | -0.183 |
| Net loss per common share, diluted | -0.07 | -0.09 | -0.17 | -0.183 |
| Weighted average common shares outstanding, basic | 100,869,349 | 95,459,401 | 74,254,700 | 1,699,549 |
| Weighted average common shares outstanding, diluted | 100,869,349 | 95,459,401 | 74,254,700 | 1,699,549 |
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)